REXULTI® (Brexpiprazole) FDA Approved for Treating Agitation in Alzheimer's Disease Patients

REXULTI® (brexpiprazole) has been approved by the FDA for treating agitation associated with dementia due to Alzheimer's disease, making it the first and only pharmacological treatment for this indication in the US.

Why REXULTI® (brexpiprazole) agitation that may happen with

First-Ever Drug for Alzheimer's Agitation, Brexpiprazole, Nears

Michael Okun on X: Brexpiprazole (Rexulti) approved by FDA for

SLU Researcher Finds Help for Alzheimer's-Associated Agitation

FDA approves new drug for Alzheimer's-Associated agitation

Mark Oldham on X: I had no clue they were going for this

Controversy Surrounds Brexpiprazole's FDA Approval, a New

Ask the Pharmacist: New drug treats Alzheimer's agitation

FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

First FDA Approved Medication for Agitation Associated with

FDA approves first drug for agitation due Alzheimer's dementia

US FDA approves Rexulti as first drug for agitation in Alzheimer's

Rexulti (brexpiprazole) is filed in Japan for Alzheimer's

FDA AdCom votes in favour of Lundbeck's/Otsuka's Rexulti in AAD

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for